Moderna Becomes Second Company to Seek FDA Emergency Use for Covid-19 Vaccine

Moderna has now become the second company to submit their potential Covid-19 vaccine for FDA emergency use approval.  Ten days ago, Pfizer and its German partner BioNTech, also applied for regulatory approval after recording a 95% efficacy rate with no severe side effects. Moderna’s drug has also become a front runner candidate after recording similar promising results. After completing its phase 3 trials, they found their vaccine was 94.1% effective against Covid-19. Furthermore, the vaccine was proven to be 100% effective at preventing severe cases. These results were reportedly the same across all age, race and gender categories. There have also been no serious safety concerns so far with some 15,000 participants only experiencing fatigue, muscle and joint pain and headaches. While this is great news, there are still experts who remain cautiously optimistic about the vaccine. These trials are focused on preventing symptomatic disease, but it’s unclear how effective they are at stopping transmission, too.